Edelberg J M, Aird W C, Rosenberg R D
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
J Clin Invest. 1998 Jan 15;101(2):337-43. doi: 10.1172/JCI1330.
Cardiac pacemaking offers a unique opportunity for direct gene transfer into the heart. An experimental system was developed to assay the effects of transferring the human beta2 adrenergic receptor (beta2AR) under in vitro, ex vivo, and finally in vivo conditions. Constructs encoding either beta2AR or LacZ were used in chronotropy studies with isolated myocytes, and transplanted as well as endogenous murine hearts. Murine embryonic cardiac myocytes were transiently transfected with plasmid constructs. The total percentage of myocytes spontaneously contracting was greater in beta2AR transfected cells, as compared with control cells (67 vs. 42+/-5%). In addition, the percentage of myocytes with chronotropic rates > 60 beats per minute (bpm) was higher in the beta2AR population, as compared with control cells (37 vs. 15+/-5%). The average contractile rate was greater in the beta2AR transfected myocytes at baseline (71+/-14 vs. 50+/-10 bpm; P < 0.001) as well as with the addition of 10(-)3 M isoproterenol (98+/-26 vs. 75+/-18 bpm; P < 0.05). Based on these results, a murine neonatal cardiac transplantation model was used to study the ex vivo effects of targeted expression of beta2AR. The constructs were transfected into the right atrium of transplanted hearts. Injection of the beta2AR construct increased the heart rate by approximately 40% (224+/-37 vs. 161+/-42 bpm; P < 0.005). Finally, the constructs were tested in vivo with injection into the right atrium of the endogenous heart. These results were similar to the ex vivo data with injection of the beta2AR constructs increasing the endogenous heart rates by approximately 40%, as compared with control injected hearts (550+/-42 vs. 390+/-37 bpm; P < 0.05). These studies demonstrate that local targeting of gene expression may be a feasible modality to regulate the cardiac pacemaking activity.
心脏起搏为将基因直接导入心脏提供了独特的机会。我们开发了一个实验系统,以检测在体外、离体及最终在体内条件下转染人β2肾上腺素能受体(β2AR)的效果。编码β2AR或LacZ的构建体用于对分离的心肌细胞、移植的及内源性小鼠心脏进行变时性研究。用质粒构建体瞬时转染小鼠胚胎心肌细胞。与对照细胞相比,转染β2AR的细胞中自发收缩的心肌细胞总百分比更高(67%对42±5%)。此外,与对照细胞相比,β2AR组中心率>60次/分钟(bpm)的心肌细胞百分比更高(37%对15±5%)。在基线时,转染β2AR的心肌细胞平均收缩率更高(71±14对50±10 bpm;P<0.001),加入10⁻³M异丙肾上腺素后也是如此(98±26对75±18 bpm;P<0.05)。基于这些结果,使用小鼠新生心脏移植模型来研究β2AR靶向表达的离体效果。构建体被转染到移植心脏的右心房。注射β2AR构建体使心率增加了约40%(224±37对161±42 bpm;P<0.005)。最后,将构建体注射到内源性心脏的右心房进行体内测试。这些结果与离体数据相似,注射β2AR构建体使内源性心率比对照注射心脏增加了约40%(550±42对390±37 bpm;P<0.05)。这些研究表明,基因表达的局部靶向可能是调节心脏起搏活动的一种可行方式。